Salvatore Siena

TL;DR: Vaccinia and adenovirus vectors are suggested to act as vehicles in genetically engineering human DCs in the perspective of tumor-specific vaccination.

TL;DR: The phase III CORRECT trial was conducted to evaluate efficacy and safety of regorafenib in pts with mCRC who had progressed after all approved standard therapies as discussed by the authors, and the primary endpoint was overall survival (OS). Secondary endpoints included progression-free survival (PFS), overall response rate (ORR), disease control rate (DCR), safety, and quality of life.

TL;DR: The experience achieved confirms the therapeutic importance of an anthracycline-containing regimen such as ABVD as salvage treatment and as primary chemotherapy, either when combined with irradiation or cyclically alternated with MOPP.

TL;DR: The double-blind, randomized, multicenter phase III DECISION trial examined sorafenib efficacy and safety vs placebo in patients with progressive RAI-refractory differentiated thyroid cancer with promising clinical activity.

TL;DR: A novel program whereby several non-cross-resistant agents (including total body irradiation at myeloablative dose) were delivered sequentially rather than concurrently to improve the therapeutic index of high-dose therapy, which compares favorably with the activity so far reported for the most effective high- dose regimens.